CJC-1295 / Ipamorelin: an evidence-first deep dive

Already know this material? Pass the checkpoint and this lesson counts as complete.

Test out checkpoint

Test out: CJC-1295 / Ipamorelin: an evidence-first deep dive

Already know the material? Pass this checkpoint without opening the lesson first.

Get every question correct to pass.

1. A vendor sells 'CJC no DAC'. Which classic CJC-1295 result should not be automatically transferred to it?

The 5.8–8.1 day half-life reported for long-acting CJC-1295The fact that GHRH signalling existsThe existence of the pituitary glandThe amino-acid concept

2. What evidence exists for ipamorelin in humans?

Early pharmacokinetic/pharmacodynamic studies showing GH releaseLarge Phase 3 body-composition trialsAn FDA-approved anti-ageing indicationNo human evidence of any kind

3. Which statement is too strong?

Separate CJC-1295 and ipamorelin studies prove the popular combination improves recoveryThe components influence the GH axis through different receptorsDirect combination evidence is limitedProduct identity matters

4. Why is product identity part of evidence interpretation?

A label saying 'CJC' may refer to DAC, no-DAC or unclear material with different exposureProduct identity never mattersAll peptide powders have the same pharmacokineticsOnly price determines identity

5. Which summary best fits CJC-1295 / Ipamorelin?

Human component pharmacology, plausible pairing, limited direct evidence for the marketed combinationApproved combination therapyNo biological rationaleLarge controlled outcome evidence for anti-ageing

PThe Pep Report

Educational information only. Not medical advice.

Personalised Guide Safety & info Research Sourcing Guide